and mass, with more concentric remodelling, lower systolic (LV ejection fraction, longitudinal and circumferential global peak systolic strain) and diastolic function (longitudinal and circumferential peak early diastolic strain rates) than females. Late gadolinium enhancement (LGE) was more prevalent (51.1% vs. 34.1%, p=0.038) and extent of LGE was also higher in males, as was Syndecan-4 and MMP-3 levels. Extracellular volume (ECV) was marginally higher in female patients. Stress and rest myocardial blood flow (MBF) were significantly lower in males, with no difference in myocardial perfusion reserve. Conclusions Male patients with AS have more concentric remodelling, worse cardiac function and more fibrosis than females, with biomarkers associated with fibrosis being significantly higher as well, for a similar degree of AS.
Abstract 129 Table 1 Male (n=133) Female (n=41) Background Left ventricular hypertrophy (LVH) assessment by ECG voltage or image based mass volume is commonly used in clinical practice and research. Our previous study of LVH regression after AVR for AS demonstrated a more complete regression in ECG voltage than in LV mass, thus indicated that ECG and Echo could be quantifying different aspects of LVH. In this study, we used gene expression profiling to examine whether different molecular pathways are involved in LV hypertrophy defined by ECG voltage or Echo LV mass. Material and Methods We studied 17 patients with aortic stenosis, aged 73±8.5 years with 12 males. Gene expression profiling of LV myocardium biopsy during AVR was carried out using Stanford Human Exonic Evidence Based Oligonucleotide (HEEBO) array. Using ECG QRS voltage cut-off 3.0 mv, 8 patients had LVH (ECG-LVH) and 9 had not (ECG-Norm ). Using Echo LV mass index 125 g/m2 for man and 105 g/m2 for woman, 9 cases had LVH (Echo-LVH) and 8 had not (Echo-Norm). The gene expression profiling comparisons were carried out between ECG-LVH vs. ECG-Norm as well as Echo-LVH vs. Echo-Norm, respectively, by parametric permutative (permutation times=1000) t-test using the pvalue cut-off 0.01. Further gene functional annotation clusters were performed using Database for Annotation, Visualisation and Integrated Discovery (DAVID, NIH) and pathway analysed by GeneSpring GX10. Results There are 163 genes significantly differentially expressed (DEGs) between ECG-LVH and ECG-Norm. Among which, 81 genes were up-regulated and 82 genes down-regulated in ECG-LVH. Between Echo-LVH and Echo-Norm, 256 DEGs were identified, of which 141 genes were up and 115 genes were down regulated in Echo-LVH. The Direct Interaction Network of 163 DEGs in ECG-LVH revealed several connected island hubs with genes of HGF, CDK5RAP2, FYN (up-regulated) and IL6, PTBP2 and IRF1 (down-regulated). Of 257 DEGs in Echo-LVH, there were more abundant islandlike connexions. The hubs of the connexion include PTEN, GNL3, AREG, ADAM17 and PPP1CA (up-regulated) and DCTN6, TWIST1 and ITGAM (down regulated). Further data mining and analysis of the two DEGs lists using DAVID and the Significantly Enriched Core Pathways analysis has demonstrated that the DEGs of ECG-LVH and ECHO-LVH have similar regulation directions in pathways/annotation clustering, including transcription regulation, nucleotide binding, zinc finger, focal adhesion. In addition, ECG-LVH has down regulation in wounding healing/inflammatory/cytokines pathway indicating a lower interstitial fibrosis activity compared with ECG-Norm; In Echo-LVH, mitochondrial protein importing, metalloprotease/ECM remodelling and cell division pathways were up-regulated compared to Echo-Norm. Conclusions Cardiac hypertrophy diagnosed by ECG voltage or Echo muscle mass share many common molecular pathways that have been implicated in LVH. The unique pathways associated with ECG voltage based LVH imply a predominant hypertrophy of myocytes; in contrast, Echo mass based LVH involves the unique pathways of myocardial energy and ECM remodelling. The convergence and divergence of underlying molecular pathways between ECG based and Echo based LVH suggest the two methods may provide complimentary clinical value in the assessment of LVH and its response to treatment. Patients with ICD (n=20) were followed up for 52.6 months±5.8 months. One patient with ICD 1* had VA detected after 7 months of ICD insertion and treated successfully with 1 anti-tachycardia pacing algorithm. Conclusion The detection of HCM through use of MRI allows for earlier diagnosis of patients and provides for accurate and reproducible measurements of LV wt and LV IBSA x as opposed to TTE. In our retrospective study it is suggested that higher LV IBSA is related to increase incidence of VA. If LV IBSA derived from MRI were applied to ESC guidelines, this could result in more patients ICD 1* . We feel this should be explored with larger studies to see if LV IBSA is an independent risk factor for SCD. Asymptomatic patients may exhibit symptoms during objective exercise testing, but whether symptoms are due to the obstructivity of the valve (typified by the mean gradient) or underlying ventricular function remains unknown. While the mean gradient is an easy parameter to measure no consensus about the measurement of contractile reserve exists. Longitudinal abnormalities may occur in the presence of a normal ejection fraction and the augmentation of these parameters is poorly described. The aim of this study was to examine the echocardiographic predictors of exercise ability during cardiopulmonary exercise testing combined with stress echocardiography.
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LEFT VENTRICULAR INDEXED MASS ASSOCIATED WITH VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY -A TERTIARY CENTRE MRI REGISTRY
THE IMPORTANCE OF CONTRACTILE RESERVE WHEN ASSESSING ASYMPTOMATIC PATIENTS WITH AORTIC STENOSIS
24 asymptomatic patients with moderate to severe or severe aortic stenosis and preserved ejection fraction underwent stress echocardiography with simultaneous cardiopulmonary exercise testing. The primary assessment of exercise ability was VO 2 peak. Echocardiography was measured at rest and during maximal exercise (defined as RER>1)
VO 2 peak showed a poor relationship with conventional resting parameters of severity including peak velocity (rho=0.07; p=ns), mean pressure gradient (rho=0.3; p=ns), AVA (rho=0.4; p=ns), dimensionless index (rho=0.05; p=ns), resting systolic function (by EF (rho=À0.18; p=ns) and TDI (rho=0.39; p=ns). During exercise systolic augmentation had a good relationship with exercise ability (rho=0.77; p<0.0001) but the relationship with exercise mean gradient was weaker (rho=0.57; p=0.005) and there was no relationship with exercise LVEF (rho=0.18; p=ns).
Longitudinal systolic function during peak exercise is the strongest predictor of exercise ability when compared to conventional measures of severity of aortic stenosis.
Introduction Hypertrophic cardiomyopathy (HCM) is the largest cause of sudden cardiac death in athletes. Differentiation between HCM and athletic cardiac adaptation is not always straightforward. Cardiopulmonary exercise testing (CPET) is useful in this context, with a peak VO 2 >120% predicted commonly used to differentiate athletes with HCM from those with physiological left ventricular hypertrophy. This value however is derived from a predominantly white population. Differences with ethnicity have been well documented on the ECG and echocardiogram of both athletes and individuals with HCM, however, ethnic differences in their physiology have not been well investigated to date. Purpose To assess if there is a significant difference on CPET in HCM patients of black and white ethnicity. Methods Cardiopulmonary exercise testing data was prospectively and retrospectively analysed from a cohort of 49 sedentary HCM patients assessed in a quaternary referral centre (36 white, 38 male; aged 15-65 years). Inclusion criteria: HCM patients of black or white ethnicity, NYHA 1, resting LVOT gradient<40 mmHg, no ICD in-situ and having completed a maximal CPET (defined as: R 1.1 and test terminated due to breathlessness/muscular fatigue).
